



Investor Connect Sessions

David Radford – CEO & MD



IMPORTANT NOTICE

SCOPE & LIMITATIONS

This Presentation has been prepared by AnteoTech Ltd (**AnteoTech** or the **Company**) (ASX.ADO). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

PLATFORM TECHNOLOGY DRIVING THE FUTURE


Proven technologies for the rapidly growing battery anode and life science diagnostics markets



Clean Energy Technology

Anteo X™

Anteo X™ is a **performance enhancing additive** enabling the move to high silicon containing anodes demonstrating **improved performance** in lithium-ion batteries



Ultranode™


AnteoTech's **Ultra High Silicon Anode** is a **proprietary high silicon anode** offering increased energy capacity, faster charging and low cost



Life Sciences

AnteoBind™ & AnteoBind NXT™

AnteoTech's **unique products** that offer significant productivity benefits in the manufacture of diagnostic products



Development Services

SILICON: THE FUTURE OF BATTERY ANODES


The shift to silicon anodes provides a **technological performance improvement** which can accelerate the clean energy transition.

Silicon a technological leap

- **Performance:** Up to 35% increase in energy density
- **Cost reduction:** 8.5x cheaper per kWh potential
- **Sustainability:** Reduces battery size and material usage
- **Utilisation of** existing manufacturing infrastructure

Strategic Supply Chain Advantages

- **Silicon is Plentiful** – Silicon is **widely available** and can be sourced locally unlike graphite (>70% graphite from China).
- **Reduced Supply Chain Risk** – Diversifies raw material sourcing and **lowers geopolitical exposure** in battery manufacturing.
- **Scalability & Cost Reduction** – Advancements in **silicon processing** are making it more cost-effective for mass production.



SILICON THE SOLUTION TO RANGE ANXIETY


Ultranode™ uses a silicon-based anode to store more energy in the same volume compared to traditional graphite, leading to longer range and potential for faster charging.

- >70% silicon active material
- Demonstrated 900 cycles at 70% capacity retention
- Roadmap to >1,000 cycles
- Use of lowest cost readily available silicon



ULTRANODE

Ultranode™ harnesses readily available silicon to revolutionise battery technology with enhanced performance and sustainability.



EVs TODAY

0-10%
Silicon content

**450km¹
Driving
range**

 Cell 626 Wh/l⁴

Standard Battery Pack³




AnteoTech Ultranode Target

>70%
Silicon content

+144Km **594 km²
Driving
range**

 Cell 826 Wh/l²

32%↑ in Wh per cell volume³



1. Tesla Model Y - <https://ev-database.org/car/3104/Tesla-Model-Y-Long-Range-AWD>

2. Internal modelling based on targeted Ultranode capacity and Tesla Model Y data. Values subject to change based on cell form factors and cell component choices. 3. Battery Pack Illustrative only

4. <https://www.batemo.com/products/batemo-cell-explorer/unknown-manufacturer-tesla-model-y-4680/>

CLEAN ENERGY – NEAR-TERM OPPORTUNITIES

Key targets to building revenue for Anteo X™ and Ultranode™




Electric Vehicles

Mercedes-Benz

- Support ongoing evaluation of Anteo X™ and Ultranode™
- Ultranode™ agreement– Target 2H25
- Target Anteo X™ sales for next gen. batteries

EV2 & EV3

- Ongoing discussions as they focus on next generation battery developments with high performance and lowest delivered cost per kW/h



Advanced Chemistries

Separator Technology

- Confirmation that Anteo X™ reduces shrinkage > safer batteries
- Optimisation of formulation
- Target commercial agreement for Anteo X™

Carbon Nano Tubes

- Confirmation Anteo X™ delivers expected performance improvements
- Partner validation then targeting commercial agreement to develop enhanced products with Anteo X™



Consumer & Medical

Wyon

- Leverage recent visit and move to high silicon anode sales.

Consumer Battery

- Target Commercial agreement in US for mobile phone batteries
- Development agreement with niche high performance battery company
- Leverage Intl Sales Directors relationships across the industry

LIFE SCIENCES – TARGETING INDIAN GROWTH OPPORTUNITIES

Building revenue streams for AnteoBind and AnteoBind NXT



US\$1.8m min. Purchase Agreement – 5 years

Business Development Targets – Vidcare

Indian market expansion

Evaluation underway

- Continue to expand usage in current vaccine program QA
- Expand into new vaccine development programs
- Expand relationship through assay development services
- Explore growth in SII-Lateral flow and other diagnostic tests

- Management meeting planned in India in 2HFY25
- Completing validation of AnteoBind NXT in the initial PoC test for India
- Proprietary in-home test for diagnosis of hypothyroidism (or underactive thyroid)

- Targeted strategy for multiple Indian PoC companies
- Rapidly expanding healthcare sector with increasing demand for advanced diagnostic solutions
- Leverage Indian government “Health for All” initiatives
- Validation of AnteoBind NXT underway with several India companies

CORPORATE SNAPSHOT

Balance Sheet strengthened with new institutional shareholders joining the share register in 2024.

Market Capitalisation¹

\$46m

Cash²

\$7.4m

Debt

Nil



Capital Structure

Shares (ADO)	2,705 million
Options (ADOO)	148 million
Unlisted Options	197 million
Institutions	~6.6%
Board & Mgmt	1.5% + Options

¹ Closing share price on 5 February 2025

² As at 30 December 2024

FIVE KEY TAKEAWAYS

Addressing global challenges, supporting the transition to renewable energy and democratising healthcare in growing markets.

- 1 Near term revenue opportunities in targeted market segments.**
Opportunities across Clean Energy Technology and Life Science divisions
- 2 Next generation battery products – validated by external partners**
Two evaluations with Mercedes on track with path to potential development agreement – evaluations with other leading companies across battery sector
- 3 Clean energy revenues – platform for sales and growth**
Production Facility & Technical team in place to support near term customer requirements
- 4 Expanding usage of AnteoBind™ – world’s largest vaccine manufacturer**
Expanding usage building long term revenues
- 5 Multiple commercial milestones in 2025**
Agreements - Sales of products – Paid development activities – Partnering opportunities

David Radford

CEO & Managing Director

investors@anteotech.com

Thank you.

